National Comprehensive Cancer Network



NCCN Oncology Research Program (ORP)
NCCN Volasertib Research Grant Opportunity – Submit by October 30, 2014
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources


Moffitt Cancer Center
Tampa, Florida
800.456.3434 (888.MOFFITT)
www.moffitt.org

Learn more about clinical trials at this NCCN Member Institution.

Profile

Moffitt Cancer Center is a National Cancer Institute Comprehensive Cancer Center whose sole mission is to "contribute to the prevention and cure of cancer." Since its doors opened in 1986, Moffitt has worked to establish a tradition of excellence in patient care offered in an atmosphere characterized by compassion and hope. Moffitt is also a recognized leader in focused, innovative research and an important resource for training future scientific and clinical leaders in oncology. Combining the clinical and research sides, the Cancer Center's goal is the discovery, translation and delivery of personalized cancer care. Moffitt has been named among "America's Best Hospitals" for cancer care by U.S. News & World Report since 1999.

  • The Moffitt hospital is licensed for 206 beds, 36 of which are dedicated to the blood and marrow transplantation unit. The Cancer Center has one of the largest Blood & Marrow Transplant Programs in the Southeast, performing more than 400 transplants a year.
    • Each year the number of patients seen at Moffitt has steadily increased. For Fiscal Year 2013, inpatient admissions reached  9,373 and outpatient visits totaled more than 330,000.
  • There are currently more than 800 research faculty and research support staff combined, and more than 330,000 square feet of research space, of which almost 190,000 square feet is dedicated to wet lab space.
  • Physicians, including residents and interns, total more than 300.
  • A major economic engine, Moffitt Cancer Center employs nearly 4,300 people across four corporate entities and generates more than $1.7 billion in direct economic output.
  • At the beginning of 2013, grant funding reached $50 million, the majority of which is peer reviewed.
  • Cancer Control: Journal of the Moffitt Cancer Center is distributed to more than 15,000 cancer specialists worldwide.
  • M2Gen®, a wholly owned subsidiary of Moffitt, is expected to take the Cancer Center’s wide-ranging Total Cancer Care® initiative to a new level. M2Gen® is designed to advance the discovery, translation and delivery of personalized therapies for cancer and other diseases. Researchers are collecting tumor specimens from thousands of patients across Florida and nationwide to identify biological markers unique to each tumor. Analyzing patient response to specific treatments will lead to more individualized care with better response and fewer side effects.
  • In 2011, Moffitt opened a satellite facility near International Plaza in Tampa to provide expanded and more easily accessible patient services. Planning for a 200,000-square-foot outpatient facility slated to open in 2015 is well underway. The McKinely campus site will house clinics, screening services, an ambulatory surgery center, infusion and imaging facilities, research labs, and space for blood draws

Clinical Programs

Optimal care at Moffitt proceeds from an interdisciplinary team approach to the evaluation and treatment of patients with cancer. In support of this philosophy, academic and clinical services have been organized into more than a dozen disease-oriented programs. The interdisciplinary programs represent patient care, clinical research, education and cancer control activities. Each has a designated leader, and the full team consists of medical oncologists, surgeons, radiation oncologists, pathologists, nurses, data and administrative managers, and other appropriate support personnel. The goals are to provide comprehensive care for new and established patients, develop and conduct clinical research trials, establish collaborative links with appropriate basic science programs, and provide educational and training programs for medical students.


Research

Each scientific research program at Moffitt Cancer Center is composed of scientific faculty selected for their high level of accomplishment and desire to work in a highly collaborative environment. Research initiatives focus on a variety of areas including: functional genomics/proteomics; immunotherapy vaccines; new drug therapies; molecular signatures; behavioral oncology, and tobacco research.
The synergy between our researchers and clinicians furthers the efforts in finding cures for cancer by moving discoveries quickly from the laboratory bench to the patient’s bedside.

Scientific programs include:

  • Cancer Biology and Evolution
  • Cancer Epidemiology
  • Chemical Biology and Molecular Medicine
  • Health Outcomes and Behavior
  • Immunology

Moffitt has an established reputation for “translational research” – fast-tracking laboratory successes into new treatments. The average number of interventional clinical trials for adults at Moffitt is 400, through cooperative groups as well as those initiated by Moffitt's own scientists.

Cancer Prevention and Control

Moffitt Cancer Center Screening and Prevention plays a central role in Moffitt’s mission to contribute to the prevention and cure of cancer. It is the cancer prevention clinical research laboratory for Moffitt. In addition to providing a population base for prevention studies, it offers a wide range of clinical cancer screening services and extensive community education outreach opportunities.

Moffitt Cancer Center Screening and Prevention provides the latest in cancer genetics research and screening technologies for breast, cervical, colorectal, prostate, ovarian and skin cancer as well as preventive counseling. Through these services Moffitt aims to help high-risk patients and families understand and reduce their risk of developing cancer. Additional services available include Cancer Answers, a toll-free cancer information line staffed by experienced registered nurses who can provide information related to cancer.

 

Strategic Alliances

To further the mission of contributing to the prevention and cure of cancer, Moffitt Cancer Center collaborates with respected academic, research, educational and regional care centers, and referring physicians known as the Moffitt Oncology Network.

Wholly committed to Moffitt’s model of patient-centered, integrated cancer care, the Moffitt Oncology Network is helping Moffitt develop a premier cancer care delivery system, focused solely on providing patients the best personalized cancer care. The Moffitt Oncology Network implements Moffitt’s Clinical Care Model, including multidisciplinary cancer care, peer review, clinical pathways and quality assurance.

In addition Moffitt has relationships with the University of Puerto Rico and the Ponce School of Medicine in Puerto Rico and institutions in Central and South America.

 

TOTAL CANCER CARE

Moffitt’s Total Cancer Care® initiative is a comprehensive approach to cancer care. It is designed to enable researchers and caregivers to identify and meet all the needs of our patients and their families during the patients’ lifetime and for future generations. The holistic approach includes all aspects of the disease, including prevention, genetic predispositions, the impact of health lifestyles and integrative medicine.

The Total Cancer Care® Study is a national research protocol open at Moffitt and at participating Total Cancer Care® Consortium sites throughout Florida and nationwide. The tissue specimens of consenting patients enrolled in the study are stored at Moffitt’s biotechnology subsidiary, M2Gen®. M2Gen® assists in the collection and processing of Total Cancer Care® Consortium Site data. Researchers study the genetics of these specimens to pinpoint biomarkers for identifying patients at risk, to discover cellular targets for engineering new cancer drugs and to develop targeted therapies. Physicians would be able to contact patients if new information, including novel clinical studies, is discovered that could help in their care. Additionally, Moffitt’s Patient Portal allows patients to schedule appointments online, and it offers cancer survivors access to a summary of their treatment, as well as a personalized survivorship care plan.
Moffitt researchers hope to use the data collected to recommend individualized treatments for patients, leading to personalized cancer care for cancer patients in their own communities throughout Florida and beyond.